OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Lattanzi on the Investigation of PARP Inhibitor Combinations in mCRPC

April 24th 2024

Mike Lattanzi, MD, discusses clinical trials that have evaluated the use of PARP inhibitor–based combination regimens in patients with mCRPC.

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer

April 24th 2024

Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.

Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL

April 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

Dr. Tiwari on Ongoing Research in HER2+/HER2-Low Breast Cancer

April 24th 2024

Shruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.

Dr Townsend on the Genetic Evolutionary Trajectory of Prostate Cancer

April 24th 2024

Jeffrey P. Townsend, PhD, on a novel approach to comprehending the evolutionary trajectory of prostate cancer through genetic profiling.

Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC

April 24th 2024

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

April 24th 2024

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

April 24th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian Cancer

April 23rd 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Dizon on the Future of Precision Medicine in Ovarian Cancer Management

April 23rd 2024

Don S. Dizon, MD, FACP, FASCO, discusses future directions for precision medicine approaches in ovarian cancer.

Dr Garje on the Use of Genomic Testing and Targeted Therapy in Prostate Cancer

April 23rd 2024

Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

April 23rd 2024

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

Dr Srour on the Ongoing Investigation of CAR T-Cell Therapy in Advanced RCC

April 23rd 2024

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Dr Nanda on the Evolution of Treatment For HER2-Low Breast Cancer

April 23rd 2024

Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.

Dr Narayan on the Mechanism of Action of Nadofaragene Firadenovec in NMIBC

April 23rd 2024

Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.

Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma

April 23rd 2024

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC

April 22nd 2024

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

April 19th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.